title: [Pharmacological prevention of cardiovascular diseases in general practice].
abstract: BACKGROUND
  In this paper the Norwegian College of General Practitioners, Working Group on Hypertension report recommendations for primary preventive drug treatment of elevated cardiovascular risk.
  
  
  METHODS
  Updated metaanalyses and randomised controlled trials are the main basis for the recommendations. The purpose of treating hypertension is prevention of cardiovascular diseases. Drug treatment with documented effect on morbidity and mortality is therefore recommended. We have also evaluated the cost effectiveness of drug treatment.
  
  
  RESULTS
  An estimate of the total risk of future cardiovascular disease is a necessary basis for treatment decisions. This paper presents tools for estimating total cardiovascular risk. Drug treatment is recommended if ten-year risk exceeds 20% or blood pressure equals or exceeds 170/100 mmHg. Drug treatments include antihypertensive, antithrombotic, antidiabetic and lipid-lowering drugs with documented effect on hard endpoints. Aspirin, thiazides, betablockers, metformin, calcium blockers, ACE inhibitors and statins are all drugs with documented effects on significant endpoints, but the costs of these treatments differ substantially.
  
  
  CONCLUSIONS
  Drug treatment to prevent cardiovascular disease should be recommended for patients at significant risk of cardiovascular disease. Drugs with documented effect on morbidity and mortality should be used. Considerations of costs are important in treatment decisions.
authors.affiliation: Institutt for samfunnsmedisinske fag, Universitetet i Bergen. Eivind.Meland@isf.uib.no
authors.forename: E
authors.initials: E
authors.lastname: Meland
authors.forename: H
authors.initials: H
authors.lastname: Ellekjaer
authors.forename: B
authors.initials: B
authors.lastname: Gjelsvik
authors.forename: A
authors.initials: A
authors.lastname: Kimsås
authors.forename: J
authors.initials: J
authors.lastname: Holmen
authors.forename: I
authors.initials: I
authors.lastname: Hetlevik
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage; D001581:Benzothiadiazines; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004232:Diuretics; D005194:Family Practice; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D009664:Norway; D017410:Practice Guidelines as Topic; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage
chemical_list: D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D005343:Fibrinolytic Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D049993:Sodium Chloride Symporter Inhibitors; D001241:Aspirin